<DOC>
	<DOCNO>NCT00864838</DOCNO>
	<brief_summary>The purpose study evaluate effect anterior chamber paracentesis , brimonidine oral acetazolamide reduce intra-ocular pressure variation intravitreal bevacizumab injection .</brief_summary>
	<brief_title>Oral Acetazolamide , Brimonidine Tartarate , Anterior Chamber Paracentesis Ocular Hypertension Control After Intravitreal Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>Diagnosis age relate macular disease diabetic retinopathy Able willing provide inform consent History ocular hypertension glaucoma High Myopes ( &gt; 6 spherical diopter ) High Hyperopes ( &gt; 4 spherical diopter ) Pulmonary disease Renal disease Known allergy component study drug Myocardial infarction , transient ischemic attack within 4 month prior randomization contraindication bevacizumab use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>intraocular pressure</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>acetazolamide</keyword>
	<keyword>brimonidine</keyword>
	<keyword>anterior chamber paracentesis</keyword>
</DOC>